S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Infinity Pharmaceuticals Stock Forecast, Price & News

-0.04 (-6.35%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
20,486 shs
Average Volume
909,791 shs
Market Capitalization
$52.60 million
P/E Ratio
Dividend Yield
Price Target

Infinity Pharmaceuticals MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
1,058.2% Upside
$6.83 Price Target
Short Interest
5.11% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($0.55) to ($0.63) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.43 out of 5 stars

Medical Sector

1016th out of 1,428 stocks

Pharmaceutical Preparations Industry

498th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive INFI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Infinity Pharmaceuticals logo

About Infinity Pharmaceuticals (NASDAQ:INFI) Stock

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

INFI Stock News Headlines

Infinity Pharmaceuticals Q4 2021 Earnings Preview
Infinity Pharmaceuticals Earnings Preview
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$1.86 million
Book Value
$0.24 per share


Free Float
Market Cap
$52.60 million

Social Links

Infinity Pharmaceuticals Frequently Asked Questions

Should I buy or sell Infinity Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Infinity Pharmaceuticals stock.
View analyst ratings for Infinity Pharmaceuticals
or view top-rated stocks.

What is Infinity Pharmaceuticals' stock price forecast for 2022?

6 analysts have issued 1-year target prices for Infinity Pharmaceuticals' stock. Their INFI stock forecasts range from $3.00 to $14.00. On average, they anticipate Infinity Pharmaceuticals' share price to reach $6.83 in the next twelve months. This suggests a possible upside of 1,058.2% from the stock's current price.
View analysts' price targets for Infinity Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Infinity Pharmaceuticals' stock price performed in 2022?

Infinity Pharmaceuticals' stock was trading at $2.25 at the start of the year. Since then, INFI shares have decreased by 73.8% and is now trading at $0.59.
View the best growth stocks for 2022 here

When is Infinity Pharmaceuticals' next earnings date?

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, July 26th 2022.
View our earnings forecast for Infinity Pharmaceuticals

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) issued its earnings results on Tuesday, May, 3rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.14). The biotechnology company earned $0.65 million during the quarter, compared to analysts' expectations of $0.40 million. Infinity Pharmaceuticals had a negative trailing twelve-month return on equity of 175.11% and a negative net margin of 2,254.97%. During the same quarter last year, the company posted ($0.15) EPS.
View Infinity Pharmaceuticals' earnings history

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the following people:
  • Ms. Adelene Q. Perkins, Chairman & CEO (Age 62, Pay $1.15M)
  • Dr. Stephane Peluso Ph.D., Chief Scientific Officer (Age 52, Pay $577.63k)
  • Dr. Robert Ilaria Jr., M.D., Chief Medical Officer (Age 61, Pay $643.54k)
  • Dr. Lawrence E. Bloch J.D., M.D., Pres & Treasurer (Age 56)
  • Ms. Melissa Hackel, VP of Fin.
  • Dr. Jeffery L. Kutok M.D., Ph.D., Chairman of Scientific Advisory Board (Age 55)
  • Mr. Seth A. Tasker J.D., Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 43)
  • Ms. Rossitza Alargova Ph.D., Head of Pharmaceutical Devel.
  • Jayne Kauffman, Sr. Exec. Coordinator

What is Adelene Q. Perkins' approval rating as Infinity Pharmaceuticals' CEO?

10 employees have rated Infinity Pharmaceuticals CEO Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among Infinity Pharmaceuticals' employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Infinity Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $0.59.

How much money does Infinity Pharmaceuticals make?

Infinity Pharmaceuticals (NASDAQ:INFI) has a market capitalization of $52.60 million and generates $1.86 million in revenue each year. The biotechnology company earns $-45,260,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Infinity Pharmaceuticals have?

Infinity Pharmaceuticals employs 23 workers across the globe.

When was Infinity Pharmaceuticals founded?

Infinity Pharmaceuticals was founded in 2000.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The official website for Infinity Pharmaceuticals is www.infi.com. The biotechnology company can be reached via phone at (617) 453-1000, via email at irpr_info@infi.com, or via fax at 617-453-1001.

This page (NASDAQ:INFI) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.